Previous Close | 0.2423 |
Open | 0.2450 |
Bid | 0.2250 x 2200 |
Ask | 0.2315 x 1000 |
Day's Range | 0.2400 - 0.2500 |
52 Week Range | 0.0850 - 3.5900 |
Volume | |
Avg. Volume | 2,053,078 |
Market Cap | 13.054M |
Beta (5Y Monthly) | 2.23 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.8800 |
Earnings Date | Mar 19, 2024 - Mar 24, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 0.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for GRTX
The recent 19% drop in Galera Therapeutics, Inc.'s ( NASDAQ:GRTX ) stock could come as a blow to insiders who purchased...
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended Se
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder value MALVERN, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy